Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2b study of Omilancor ulcerative Colitis

Next Previous
Search
Trial Profile

Phase 2b study of Omilancor ulcerative Colitis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omilancor (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use

Most Recent Events

  • 28 Mar 2022 New trial record
  • 24 Mar 2022 According to a Landos Biopharma media release, According to a Landos Biopharma media release, the company completed an exhaustive re-analysis of the Phase 2 data in Q1 2022 and a re-evaluation of doses and drug product formulations. These ongoing efforts will help guide the design of this study.
  • 24 Mar 2022 According to a Landos Biopharma media release, the company expect to initiate this trial later this year.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top